Click here to get full coverage on What momentum shifts mean for CERO - July 2025 Reactions & Free Reliable Trade Execution Plans - newser.com

What momentum shifts mean for CERO - July 2025 Reactions & Free Reliable Trade Execution Plans  newser.com

What momentum shifts mean for CERO - July 2025 Reactions & Free Reliable Trade Execution Plans - newser.com

Click here to get full coverage on How Corona Cero mixed AI, human insights to find Olympic gold - Marketing Dive

How Corona Cero mixed AI, human insights to find Olympic gold  Marketing Dive

How Corona Cero mixed AI, human insights to find Olympic gold - Marketing Dive

Click here to get full coverage on CERo commences second cohort of AML trial - Clinical Trials Arena

CERo commences second cohort of AML trial  Clinical Trials Arena

CERo commences second cohort of AML trial - Clinical Trials Arena

Click here to get full coverage on Macquarie shifts Corio and Cero to corporate arm ahead of green asset sales - Infrastructure Investor

Macquarie shifts Corio and Cero to corporate arm ahead of green asset sales  Infrastructure Investor

Macquarie shifts Corio and Cero to corporate arm ahead of green asset sales - Infrastructure Investor

Click here to get full coverage on CERo Therapeutics Announces Receipt of Nasdaq Panel Determination - GlobeNewswire

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination  GlobeNewswire

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination - GlobeNewswire

Click here to get full coverage on Will CERO stock beat EPS estimates - Quarterly Trade Report & Expert Verified Stock Movement Alerts - newser.com

Will CERO stock beat EPS estimates - Quarterly Trade Report & Expert Verified Stock Movement Alerts  newser.com

Will CERO stock beat EPS estimates - Quarterly Trade Report & Expert Verified Stock Movement Alerts - newser.com

Click here to get full coverage on CERo Therapeutics Announces Listing on OTC Markets - Yahoo Finance

CERo Therapeutics Announces Listing on OTC Markets  Yahoo Finance

CERo Therapeutics Announces Listing on OTC Markets - Yahoo Finance

Click here to get full coverage on CERo Therapeutics (NASDAQ: CERO) denied over $2.5M equity rule; suspended Oct. 31 - Stock Titan

CERo Therapeutics (NASDAQ: CERO) denied over $2.5M equity rule; suspended Oct. 31  Stock Titan

CERo Therapeutics (NASDAQ: CERO) denied over $2.5M equity rule; suspended Oct. 31 - Stock Titan

Click here to get full coverage on Why Is CERo Therapeutics Stock Down 80% Today? - TipRanks

Why Is CERo Therapeutics Stock Down 80% Today?  TipRanks

Why Is CERo Therapeutics Stock Down 80% Today? - TipRanks

Click here to get full coverage on CERo Therapeutics denied Nasdaq listing, seeks OTC markets - Seeking Alpha

CERo Therapeutics denied Nasdaq listing, seeks OTC markets  Seeking Alpha

CERo Therapeutics denied Nasdaq listing, seeks OTC markets - Seeking Alpha

Click here to get full coverage on CERo Therapeutics Completes First Tranche of $7 Million Financing to Support Clinical Development and Nasdaq Compliance - Quiver Quantitative

CERo Therapeutics Completes First Tranche of $7 Million Financing to Support Clinical Development and Nasdaq Compliance  Quiver Quantitative

CERo Therapeutics Completes First Tranche of $7 Million Financing to Support Clinical Development and Nasdaq Compliance - Quiver Quantitative

Click here to get full coverage on CERo concludes first cohort of CER-1236 trial in AML - Clinical Trials Arena

CERo concludes first cohort of CER-1236 trial in AML  Clinical Trials Arena

CERo concludes first cohort of CER-1236 trial in AML - Clinical Trials Arena

Click here to get full coverage on CERo (NASDAQ: CERO) completes $7M financing tranche as trial adds third CER-1236 dose - Stock Titan

CERo (NASDAQ: CERO) completes $7M financing tranche as trial adds third CER-1236 dose  Stock Titan

CERo (NASDAQ: CERO) completes $7M financing tranche as trial adds third CER-1236 dose - Stock Titan

Click here to get full coverage on CERo Therapeutics Faces Nasdaq Delisting Suspension - TipRanks

CERo Therapeutics Faces Nasdaq Delisting Suspension  TipRanks

CERo Therapeutics Faces Nasdaq Delisting Suspension - TipRanks

Click here to get full coverage on Published on: 2025-11-13 02:17:49 - newser.com

Published on: 2025-11-13 02:17:49  newser.com

Published on: 2025-11-13 02:17:49 - newser.com

Click here to get full coverage on Will CERO stock beat EPS estimates - 2025 Major Catalysts & Target Return Focused Picks - newser.com

Will CERO stock beat EPS estimates - 2025 Major Catalysts & Target Return Focused Picks  newser.com

Will CERO stock beat EPS estimates - 2025 Major Catalysts & Target Return Focused Picks - newser.com

Click here to get full coverage on Can you recover from losses in CERO - Portfolio Gains Report & Technical Confirmation Trade Alerts - newser.com

Can you recover from losses in CERO - Portfolio Gains Report & Technical Confirmation Trade Alerts  newser.com

Can you recover from losses in CERO - Portfolio Gains Report & Technical Confirmation Trade Alerts - newser.com

Click here to get full coverage on What analyst consensus says on CERO stock - July 2025 Review & Daily Chart Pattern Signals - newser.com

What analyst consensus says on CERO stock - July 2025 Review & Daily Chart Pattern Signals  newser.com

What analyst consensus says on CERO stock - July 2025 Review & Daily Chart Pattern Signals - newser.com

Click here to get full coverage on Real time breakdown of CERO stock performance - 2025 Biggest Moves & Daily Stock Trend Watchlist - newser.com

Real time breakdown of CERO stock performance - 2025 Biggest Moves & Daily Stock Trend Watchlist  newser.com

Real time breakdown of CERO stock performance - 2025 Biggest Moves & Daily Stock Trend Watchlist - newser.com

Click here to get full coverage on Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 2026 - Business Wire

Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 2026  Business Wire

Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 2026 - Business Wire

Click here to get full coverage on New Analyst Forecast: $CERO Given 'Hold' Rating - Quiver Quantitative

New Analyst Forecast: $CERO Given 'Hold' Rating  Quiver Quantitative

New Analyst Forecast: $CERO Given 'Hold' Rating - Quiver Quantitative

Click here to get full coverage on What Is 'Dos a Cero'? A History Of The USA-Mexico Rivalry's Signature Scoreline - FOX Sports

What Is 'Dos a Cero'? A History Of The USA-Mexico Rivalry's Signature Scoreline  FOX Sports

What Is 'Dos a Cero'? A History Of The USA-Mexico Rivalry's Signature Scoreline - FOX Sports

Click here to get full coverage on CERo Therapeutics (OTC PINK: CERO) lists on OTC Pink, exploring uplist options - Stock Titan

CERo Therapeutics (OTC PINK: CERO) lists on OTC Pink, exploring uplist options  Stock Titan

CERo Therapeutics (OTC PINK: CERO) lists on OTC Pink, exploring uplist options - Stock Titan

Click here to get full coverage on CERo (OTC PINK: CERO) doubles dose in Phase 1 AML second cohort; second dose at 48 hours - Stock Titan

CERo (OTC PINK: CERO) doubles dose in Phase 1 AML second cohort; second dose at 48 hours  Stock Titan

CERo (OTC PINK: CERO) doubles dose in Phase 1 AML second cohort; second dose at 48 hours - Stock Titan

Click here to get full coverage on Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 2026 - Morningstar

Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 2026  Morningstar

Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 2026 - Morningstar

Click here to get full coverage on CERo Therapeutics (OTC: CERO) to show CER-1236 sustained expansion, cytokine response at SITC - Stock Titan

CERo Therapeutics (OTC: CERO) to show CER-1236 sustained expansion, cytokine response at SITC  Stock Titan

CERo Therapeutics (OTC: CERO) to show CER-1236 sustained expansion, cytokine response at SITC - Stock Titan

Click here to get full coverage on Cero Therapeutics announces 1-for-20 reverse stock split - Yahoo Finance

Cero Therapeutics announces 1-for-20 reverse stock split  Yahoo Finance

Cero Therapeutics announces 1-for-20 reverse stock split - Yahoo Finance

Click here to get full coverage on AB InBev prepares Corona Cero push in Winter Olympics build-up – video - Global Drinks Intel

AB InBev prepares Corona Cero push in Winter Olympics build-up – video  Global Drinks Intel

AB InBev prepares Corona Cero push in Winter Olympics build-up – video - Global Drinks Intel

Click here to get full coverage on How analysts rate CERO stock today - 2025 Trade Ideas & Stock Portfolio Risk Management - newser.com

How analysts rate CERO stock today - 2025 Trade Ideas & Stock Portfolio Risk Management  newser.com

How analysts rate CERO stock today - 2025 Trade Ideas & Stock Portfolio Risk Management - newser.com

Click here to get full coverage on Corona Cero Surf Open Cerritos Brings High-Performance Haven Back to Qualifying Series - World Surf League

Corona Cero Surf Open Cerritos Brings High-Performance Haven Back to Qualifying Series  World Surf League

Corona Cero Surf Open Cerritos Brings High-Performance Haven Back to Qualifying Series - World Surf League

Click here to get full coverage on ‘Dos a Cero’ Strikes Again: Why the USMNT Loves Playing in Columbus, Ohio - US Soccer

‘Dos a Cero’ Strikes Again: Why the USMNT Loves Playing in Columbus, Ohio  US Soccer

‘Dos a Cero’ Strikes Again: Why the USMNT Loves Playing in Columbus, Ohio - US Soccer

Click here to get full coverage on D. Boral Capital Maintains CERo Therapeutics Holdings (CERO) Buy Recommendation - Nasdaq

D. Boral Capital Maintains CERo Therapeutics Holdings (CERO) Buy Recommendation  Nasdaq

D. Boral Capital Maintains CERo Therapeutics Holdings (CERO) Buy Recommendation - Nasdaq

Click here to get full coverage on CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - GlobeNewswire

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split  GlobeNewswire

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - GlobeNewswire

Click here to get full coverage on Oct 22: CERo CEO Chris Ehrlich to join stem cell therapy panel at Maxim Growth Summit; webcast and 90-day replay - Stock Titan

Oct 22: CERo CEO Chris Ehrlich to join stem cell therapy panel at Maxim Growth Summit; webcast and 90-day replay  Stock Titan

Oct 22: CERo CEO Chris Ehrlich to join stem cell therapy panel at Maxim Growth Summit; webcast and 90-day replay - Stock Titan

Click here to get full coverage on No DLTs in Cohort 1 — CERo Therapeutics advances dose‑finding, to enroll 3 patients with planned dose increase - Stock Titan

No DLTs in Cohort 1 — CERo Therapeutics advances dose‑finding, to enroll 3 patients with planned dose increase  Stock Titan

No DLTs in Cohort 1 — CERo Therapeutics advances dose‑finding, to enroll 3 patients with planned dose increase - Stock Titan

Click here to get full coverage on CERo Therapeutics open to takeover offers as it awaits key data - Axios - Investing.com

CERo Therapeutics open to takeover offers as it awaits key data - Axios  Investing.com

CERo Therapeutics open to takeover offers as it awaits key data - Axios - Investing.com

Click here to get full coverage on What institutional flow reveals about CERO - 2025 Winners & Losers & Weekly Return Optimization Alerts - newser.com

What institutional flow reveals about CERO - 2025 Winners & Losers & Weekly Return Optimization Alerts  newser.com

What institutional flow reveals about CERO - 2025 Winners & Losers & Weekly Return Optimization Alerts - newser.com

Click here to get full coverage on New Analyst Forecast: $CERO Given 'Buy' Rating | CERO Stock News - Quiver Quantitative

New Analyst Forecast: $CERO Given 'Buy' Rating | CERO Stock News  Quiver Quantitative

New Analyst Forecast: $CERO Given 'Buy' Rating | CERO Stock News - Quiver Quantitative

Click here to get full coverage on CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 - GlobeNewswire

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041  GlobeNewswire

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 - GlobeNewswire

Click here to get full coverage on Cero Therapeutics amends purchase agreement, completes initial closing for $2.25 million - Investing.com

Cero Therapeutics amends purchase agreement, completes initial closing for $2.25 million  Investing.com

Cero Therapeutics amends purchase agreement, completes initial closing for $2.25 million - Investing.com

Click here to get full coverage on CERo Therapeutics Expands Securities Purchase Agreement - TipRanks

CERo Therapeutics Expands Securities Purchase Agreement  TipRanks

CERo Therapeutics Expands Securities Purchase Agreement - TipRanks

Click here to get full coverage on First-in-Human Trial Progress: CERo Therapeutics' Novel Cell Therapy Reaches Key Milestone in AML Study - Stock Titan

First-in-Human Trial Progress: CERo Therapeutics' Novel Cell Therapy Reaches Key Milestone in AML Study  Stock Titan

First-in-Human Trial Progress: CERo Therapeutics' Novel Cell Therapy Reaches Key Milestone in AML Study - Stock Titan

Click here to get full coverage on Real time scanner hits for CERO explained - 2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com

Real time scanner hits for CERO explained - 2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications  newser.com

Real time scanner hits for CERO explained - 2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com

Click here to get full coverage on CERO Maintains "Buy" Rating with $30 Price Target by Analyst Jas - GuruFocus

CERO Maintains "Buy" Rating with $30 Price Target by Analyst Jas  GuruFocus

CERO Maintains "Buy" Rating with $30 Price Target by Analyst Jas - GuruFocus

Click here to get full coverage on John Cero Obituary (2025 - 2025) - Parkville, MD - The Baltimore Banner - Legacy

John Cero Obituary (2025 - 2025) - Parkville, MD - The Baltimore Banner  Legacy

John Cero Obituary (2025 - 2025) - Parkville, MD - The Baltimore Banner - Legacy

Click here to get full coverage on Cero seeking more safety, dosing data on T-cell therapy for AML - Rare Cancer News

Cero seeking more safety, dosing data on T-cell therapy for AML  Rare Cancer News

Cero seeking more safety, dosing data on T-cell therapy for AML - Rare Cancer News

Click here to get full coverage on CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened - Stocktwits

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened  Stocktwits

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened - Stocktwits

Click here to get full coverage on CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing - GlobeNewswire

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing  GlobeNewswire

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing - GlobeNewswire

Click here to get full coverage on CERo Therapeutics completes first cohort in leukemia treatment trial - Investing.com

CERo Therapeutics completes first cohort in leukemia treatment trial  Investing.com

CERo Therapeutics completes first cohort in leukemia treatment trial - Investing.com

Click here to get full coverage on Cero Therapeutics enters $17.5 million equity purchase agreement with investor By Investing.com - Investing.com

Cero Therapeutics enters $17.5 million equity purchase agreement with investor By Investing.com  Investing.com

Cero Therapeutics enters $17.5 million equity purchase agreement with investor By Investing.com - Investing.com

Click here to get full coverage on CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug - GlobeNewswire

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug  GlobeNewswire

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug - GlobeNewswire

Click here to get full coverage on Cero Therapeutics announces listing on OTC Markets - TipRanks

Cero Therapeutics announces listing on OTC Markets  TipRanks

Cero Therapeutics announces listing on OTC Markets - TipRanks

Click here to get full coverage on CERo announces SCRI as main site for trial of CER-1236 to treat AML - Clinical Trials Arena

CERo announces SCRI as main site for trial of CER-1236 to treat AML  Clinical Trials Arena

CERo announces SCRI as main site for trial of CER-1236 to treat AML - Clinical Trials Arena

Click here to get full coverage on Cero announces two granted U.S. patents, European patent application allowance - Yahoo Finance

Cero announces two granted U.S. patents, European patent application allowance  Yahoo Finance

Cero announces two granted U.S. patents, European patent application allowance - Yahoo Finance

Click here to get full coverage on CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia - Yahoo Finance

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia  Yahoo Finance

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia - Yahoo Finance

Click here to get full coverage on How high can CERO stock go - July 2025 Momentum & Free High Return Stock Watch Alerts - newser.com

How high can CERO stock go - July 2025 Momentum & Free High Return Stock Watch Alerts  newser.com

How high can CERO stock go - July 2025 Momentum & Free High Return Stock Watch Alerts - newser.com

Click here to get full coverage on CERo's Novel CAR-T Therapy Achieves 20.8x Cell Expansion in AML Patient as Second Patient Joins Trial - Stock Titan

CERo's Novel CAR-T Therapy Achieves 20.8x Cell Expansion in AML Patient as Second Patient Joins Trial  Stock Titan

CERo's Novel CAR-T Therapy Achieves 20.8x Cell Expansion in AML Patient as Second Patient Joins Trial - Stock Titan

Click here to get full coverage on 10/30/2025 Market Update - Winners: INTS, BQ, AQMS - Losers: CERO, MSPR, FMC - S&P 500: -1% - Trefis

10/30/2025 Market Update - Winners: INTS, BQ, AQMS - Losers: CERO, MSPR, FMC - S&P 500: -1%  Trefis

10/30/2025 Market Update - Winners: INTS, BQ, AQMS - Losers: CERO, MSPR, FMC - S&P 500: -1% - Trefis

Click here to get full coverage on FDA Fast Track Designation: CERo's Novel Cancer Immunotherapy CER-1236 Advances Against Deadly AML - Stock Titan

FDA Fast Track Designation: CERo's Novel Cancer Immunotherapy CER-1236 Advances Against Deadly AML  Stock Titan

FDA Fast Track Designation: CERo's Novel Cancer Immunotherapy CER-1236 Advances Against Deadly AML - Stock Titan

Click here to get full coverage on Cero Therapeutics adds institutional investors in Series D preferred stock sale By Investing.com - Investing.com

Cero Therapeutics adds institutional investors in Series D preferred stock sale By Investing.com  Investing.com

Cero Therapeutics adds institutional investors in Series D preferred stock sale By Investing.com - Investing.com

Click here to get full coverage on Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq

Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation  Nasdaq

Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq

Click here to get full coverage on CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 - GlobeNewswire

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236  GlobeNewswire

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 - GlobeNewswire

Click here to get full coverage on Cero Therapeutics initiates second cohort in Phase 1 trial of CER-1236 - TipRanks

Cero Therapeutics initiates second cohort in Phase 1 trial of CER-1236  TipRanks

Cero Therapeutics initiates second cohort in Phase 1 trial of CER-1236 - TipRanks

Click here to get full coverage on CERo Therapeutics Sits On A High-Risk, High-Reward Biotech Bet - Finimize

CERo Therapeutics Sits On A High-Risk, High-Reward Biotech Bet  Finimize

CERo Therapeutics Sits On A High-Risk, High-Reward Biotech Bet - Finimize

Click here to get full coverage on Cero Therapeutics to present data on CER-1236 at SITC conference - TipRanks

Cero Therapeutics to present data on CER-1236 at SITC conference  TipRanks

Cero Therapeutics to present data on CER-1236 at SITC conference - TipRanks

Click here to get full coverage on CERo Therapeutics Enters Securities Purchase Agreement - TipRanks

CERo Therapeutics Enters Securities Purchase Agreement  TipRanks

CERo Therapeutics Enters Securities Purchase Agreement - TipRanks

Click here to get full coverage on FDA Boosts CERo's Revolutionary T Cell Therapy with Orphan Drug Status for Deadly Blood Cancer - Stock Titan

FDA Boosts CERo's Revolutionary T Cell Therapy with Orphan Drug Status for Deadly Blood Cancer  Stock Titan

CERO

Price Chart

Key Statistics

Technicals

About CERO

Latest News

What momentum shifts mean for CERO - July 2025 Reactions & Free Reliable Trade Execution Plans - newser.com

How Corona Cero mixed AI, human insights to find Olympic gold - Marketing Dive

CERo commences second cohort of AML trial - Clinical Trials Arena

Advanced Charts

Top Gainers

Top Losers